Optibiotix Health Share Discussion Threads

[parob] 26/10/2017 12:37

Some info on Bob Rastall:

[parob] 26/10/2017 12:31

One of the world’s leading microbiome scientists is to present OptiBiotix Health plc’s (LON:OPTI) latest research at a large industry conference in San Diego next week.

[riskybusiness1] 26/10/2017 09:13

It's not a strain it's a prebiotic fibre extracted from the strain that enhances the strains effect threefold...a separate product from a separate division gaining commercial traction with the most recent TATA deal as manufacturer. I think the actual news is that a world renowned expert in the field is presenting Optis own research at an industry leading conference in the US - gives Optis science huge credentials. The ability to manipulate the microbiome in such a targeted way is ahead of the curve in this space and will definitely get some attention there.

[judijudi] 26/10/2017 08:25

There will come a time when those that could have brought at this price, but did not, will be kicking themselves
There will also come a time when those selling at this price, when they could have held, will be kicking themselves all around their front room!

[trotterstrading] 26/10/2017 08:16

There really is no pleasing some PI's! I think the company have the communication approach spot on. The company like to keep investors, and perspective funds up to date with developments. For those that say this is non news, I disagree. We should be shouting from the roof tops that we have one of the worlds leading experts presenting OPTI's 'world first' science and (soon to be) commercially available products.

[parob] 26/10/2017 08:11

I wonder if there's a threefold effect on blood pressure reduction too.

[john henry] 26/10/2017 08:07

This new strain could quite easily replace statins imho
Just out of interest i was talking to my sister yesterday about a friend of hers who cant sleep at night due to the side effects of statins.she has to take pain killers and anti inflams to help her sleep.

[tsmith2] 26/10/2017 08:07

Some may say peddling non news is just desperation?

[f3rdinand] 26/10/2017 08:04

No Zebbo, that's been known for some months now, although I don't feel the market understands its significance.....yet

[parob] 26/10/2017 08:02

It's not 'new' news but's it good for the market to be reminded of this huge scientific breakthrough. I wonder which US pharma companies will be in attendance for this presentation next week!? It's no surprise pharma interest is increasing.

[zebbo] 26/10/2017 07:58

Correct me if Im wrong, but is the new bit....
OptiBiotix's®cholesterol and blood pressure reducing LPLDL®strain. In the case of LPLDL®, combining it with galacto-oligosaccharides produced from it, lead to a threefold increase in the strains ability to lower cholesterol

[john henry] 26/10/2017 07:53

Looking forward to this new strain being made available.

[someuwin] 26/10/2017 07:48

It all sounds good, but I'm not sure what is new there that warrants an RNS.

[deeppockets] 26/10/2017 07:28

Keeps us firmly in the spotlight! Good that it's in the US as that's a huge market

[parob] 26/10/2017 07:20

Presentation of research
Released 07:00 26-Oct-2017

RNS Number : 6269U
OptiBiotix Health PLC
26 October 2017

OptiBiotix Health plc
("OptiBiotix" or the "Company")

Presentation of research at MicroBiome R&D and Business Collaboration: USA

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it will be presenting research data on its microbiome modulators at MicroBiome R&D and Business Collaboration (USA) in San Diego, on 2-3 November 2017. The conference is unique in that it brings together an even split of industry and academic thought leaders in microbiome research to discuss the latest developments in microbiome science, and is seen as one of the leading conferences for the development of commercial partnerships and collaborations.

OptiBiotix's® presentation will be given by Professor Bob Rastall, an international key opinion and expert on prebiotics. The presentation will cover the work the company has undertaken with the University of Reading on its OptiBiotics®: combinations of a probiotic and a targeted prebiotic specifically designed to selectively enhance the growth rate and health benefits of probiotic products. This new product concept is seen as a more rational and scientific approach to developing optimised synbiotics to enhance probiotic health benefits in the probiotic market forecast to be worth more than $46.5bn by 2020 (Markets and Markets).

The oral presentation will present research showing an approach, protected by over 19 OptiBiotix patents, in which a probiotics own metabolic machinery is used to generate an oligosaccharide that is highly metabolised by the producing strain. This approach has been used to enhance the cholesterol reducing effect of OptiBiotix's®cholesterol and blood pressure reducing LPLDL®strain. In the case of LPLDL®, combining it with galacto-oligosaccharides produced from it, lead to a threefold increase in the strains ability to lower cholesterol.

These galacto-oligosaccharides are heat resistant and stable during processing creating the potential for them to be used as functional ingredients in a wide range of food products. This extends the existing product opportunity offered by OptiBiotix's LPLDL® cholesterol reducing strain from supplements to ingredients, greatly increasing the market opportunity.

Commenting, Stephen O'Hara, CEO of OptiBiotix said: "These presentations at major international conferences are important steps in establishing the scientific maturity and credibility of our technologies. We are particularly pleased thatProfessor Bob Rastall, one of the worlds leading scientists in this field is presenting the research which was undertaken under his leadership at the University of Reading. The last 12 months has seen an increase in the number of presentations and publications on OptiBiotix's research reflecting the growing interest and maturity of our science. These presentations and publications help build awareness of OptiBiotix's technology and products in international markets and provide the scientific evidence base to support commercialisation of our next generation prebiotics, probiotics, and OptiBiotic products."

[judijudi] 26/10/2017 07:05

All slowly coming together
3 fold increase
:)

[monkeywench1] 25/10/2017 23:58

Not as obsessive as the Rampers.

[loungeact] 25/10/2017 23:40

Monkeywench starting to go down the Mickymouse obsessive nut job road...

[monkeywench1] 25/10/2017 23:21

SOH states `The cautionary statements are provided by the regulator as a requirement of release in the absence of sales figure which partners are reluctant to release. To be fair this is consistent with the approach we have always taken of building long term sustainable value rather than hyping the market.`

Yet the famous El rampo and his acolytes are doing the opposite. Oh dear..shows a little lack of respect.

[monkeywench1] 25/10/2017 23:18

Lounge act managed to mention ramping 5 times in one post. Even more impressive.

[loungeact] 25/10/2017 23:13

Ok, so I was a little off. 7 times in the last 10 posts. Still impressive. :)

[loungeact] 25/10/2017 23:09

I wonder how many times Monkeywench1 has mentioned the words "Ramping, ramp, rampy, ramppylicious, ramptastic". I'm thinking at least 85% of his posts consist of at least one of those words.

[monkeywench1] 25/10/2017 22:44

I suppose this share proves that ramping is ineffective. If we get meaningful revenues then the share price will take care of itself.

[opodio] 25/10/2017 20:20

wouldnt want to hold these on the next results
look at what happened to DEFX when forecasts are missed

loses 50 per cent

[elrico] 25/10/2017 20:02

Who knows what will move the share price north with any real momentum? I doubt it will be a UK retailer, surely we are not so blind to the potential? Some of you that have been to the investor presentations may well be familiar with OPTI's e-commerce strategy - for those that are not; OPTI are free to negotiate agreements with other companies for their strains. Part of the thinking is to using GoFigure as a shop window as it allows them to build an e-commerce website with stocking and distribution etc. Then copy this and use to sell its products in the UK. This is to meet the demand for products like LP-LDL from within the UK.

As OPTI develop formulations with partners these products can be available for consumers via the website for multiple products direct to consumer. This has little no extra cost and creates another sales opportunity at higher margin. These type of sales are expected to make up 10-12% of revenues. The aim is to build the B2B channel but also give consumers a B2C option. SOH say this strategy is to continued integration of THWLC into OPTI including utilisation of its online platform and commercial relationships as part of a natural evolution of both companies.

We should also keep in mind, the latest deal with Galenicum creates revenues from SACCO as well as Nutrillnea....minimum of three revenue streams PER PRODUCT.